Amplia Therapeutics
Amplia Therapeutics is an Australia-based biotechnology company that leads 2 cancer trials in OnCo, testing the focal adhesion kinase inhibitor narmafotinib (AMP945) in pancreatic ductal adenocarcinoma.
Overview
Amplia Therapeutics is a clinical-stage drug development company listed on the ASX that is advancing focal adhesion kinase (FAK) inhibitors for cancer and fibrosis. Its lead candidate narmafotinib (AMP945) is being studied in pancreatic cancer. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT07026279 (phase 1/2, A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With...) and NCT05355298 (phase 1/2, ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Panc...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.